Clinical News and Research

RSS

Technology development could help expand usefulness of Raman microscopy

Researchers have developed a Raman microscope that can acquire information hundreds of times faster than a conventional Raman microscope.

8 Feb 2023

Promotional spending share allocated to consumer advertising higher for drugs with low added benefit

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that the share of promotional spending allocated to consumer advertising was on average 14.3 percentage points higher for drugs with low added benefit compared to drugs with high added benefit.

8 Feb 2023

Novel combination therapy shows promise in acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive form of cancer that originates in the bone marrow, rapidly spreads to the blood and can quickly cause death if not treated promptly.

8 Feb 2023

Treating ovarian cancer with immunotherapy involving CAR T cells

Recent research revealed that CAR T-cell therapy, a particular type of cancer treatment in which the immune system’s T cells are directed to kill tumor cells, is successful in treating ovarian cancer in mice.

7 Feb 2023

CAR T-cell therapy effective in mice with ovarian cancer

CAR T-cell therapy, a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumor cells, is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.

6 Feb 2023

Groundbreaking discovery could lead to new ways of controlling gene regulation

UT Southwestern Medical Center researchers have discovered a method cells use to turn genes on and off that involves portions of proteins whose function has long been a mystery.

6 Feb 2023

Antibody that blocks VEGF-B could be a potential therapeutic option for fatty liver disease

There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases.

6 Feb 2023

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Cerba Research announced today a Memorandum of Understanding with Teddy Clinical Research Laboratory (Wuxi, China), a preeminent central lab provider covering mainland China, to lay the foundation for an in-depth discussion towards the creation of a Joint Venture.

From Cerba Research 3 Feb 2023

Employing molecular anchor for more effective CAR immunotherapies

Researchers at St. Jude Children’s Research Hospital discovered that immune cells with the attached protein boosted the killing of cancer, irrespective of the kind of cancer cell or the type of cancer being targeted.

3 Feb 2023

Experimental optimization of prime editing to achieve high efficiency

Genome editing technologies have enormous potential for treating genetic diseases. Techniques like the extensively used CRISPR/Cas9 gene scissors target the source of the disease directly in the DNA.

3 Feb 2023

Losartan prevents immunotherapy-related edema, improves survival in glioblastoma mouse models

Patients with glioblastoma-;the deadliest type of primary brain tumor-;may potentially benefit from immunotherapy medications called immune checkpoint inhibitors that stimulate an immune response against cancer cells.

3 Feb 2023

Scientists define four cancer molecular subtypes using PDX models

Metastasis, the process by which cancer cells leave the primary tumor and spread to other tissues to seed new cancerous growth, causes most cancer deaths.

2 Feb 2023

Microbiome therapeutic linked to quality of life improvement in patients with recurrent C. diff infection

Kevin Garey, professor of pharmacy practice and translational research at the University of Houston College of Pharmacy is reporting the first well-controlled study to demonstrate that a microbiome therapeutic, SER-109, is associated with significant quality of life improvement in patients with the debilitating recurrent infection and disease caused by Clostridium difficile (or C. diff).

1 Feb 2023

Study identifies genetic mutation in the SPTSSA gene as cause of Hereditary Spastic Paraplegia

A genetic mutation in the SPTSSA gene is identified as the cause of Hereditary Spastic Paraplegia, a rare disease that causes progressive weakness, stiffness and spasticity in the lower extremities, according to a study, "SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia," published in Brain on on Jan. 30.

1 Feb 2023

Clinical News and Research

Technology development could help expand usefulness of Raman microscopy

Promotional spending share allocated to consumer advertising higher for drugs with low added benefit

Novel combination therapy shows promise in acute myeloid leukemia

Treating ovarian cancer with immunotherapy involving CAR T cells

CAR T-cell therapy effective in mice with ovarian cancer

Groundbreaking discovery could lead to new ways of controlling gene regulation

Antibody that blocks VEGF-B could be a potential therapeutic option for fatty liver disease

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Employing molecular anchor for more effective CAR immunotherapies

Experimental optimization of prime editing to achieve high efficiency

Losartan prevents immunotherapy-related edema, improves survival in glioblastoma mouse models

Scientists define four cancer molecular subtypes using PDX models

Microbiome therapeutic linked to quality of life improvement in patients with recurrent C. diff infection

Study identifies genetic mutation in the SPTSSA gene as cause of Hereditary Spastic Paraplegia

Clinically approved fungal vaccine protects against fungal infections

UNC research describes another layer to the challenge of HIV latency

Combination of silver nanoparticles and antibiotics effective against antibiotic-resistant bacteria

Genomic study helps retrace origin and spread of Shigellosis outbreak in Seattle

Research supports the safety and efficacy of COVID-19 vaccination in cancer patients receiving immunotherapy

Cochlear organoids provide a platform to understand sensorineural hearing loss

Driving Support for Pharmaceutical Testing Through Continuous Innovation

From Memory to Metaplasticity: Unraveling the Brain's Secrets

Revolutionizing Mass Spectrometry: A Deep Dive into Plasmion’s SICRIT® Technology

Latest in Genomics